Short transient receptor potential channel 6 (TRPC6)
Homo sapiens — UniProt Q9Y210
Data last refreshed: (UniProt release unknown)
Key facts
Short transient receptor potential channel 6 (TRPC6) is a protein from Homo sapiens identified by UniProt accession Q9Y210, 931 residues long. MolForge cross-references it against 2 known binders and 335 disease associations.
- UniProt accession: Q9Y210; gene symbol TRPC6.
- Organism: Homo sapiens.
- Length: 931 amino acids.
- Approved drugs acting on it (DrugCentral): Clemizole and Norgestimate.
- Top disease associations (Open Targets): focal segmental glomerulosclerosis, familial idiopathic steroid-resistant nephrotic syndrome and trait in response to prednisolone.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Short transient receptor potential channel 6 |
|---|---|
| UniProt accession | Q9Y210 |
| Gene | TRPC6 |
| Organism | Homo sapiens |
| Length | 931 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (2)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (335)
Diseases linked to this target (Open Targets).
- focal segmental glomerulosclerosis · score 0.80
- familial idiopathic steroid-resistant nephrotic syndrome · score 0.65
- trait in response to prednisolone · score 0.54
- nephrotic syndrome · score 0.45
- monocyte count · score 0.41
- myeloid white cell count · score 0.40
- platelet count · score 0.39
- Proteinuria · score 0.37
- kidney failure · score 0.37
- age at menarche · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9Y210-F1 | alphafold | PREDICTED | 76.70 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y210.
Amino-acid sequence (931 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target TRPC6?
DrugCentral lists 2 approved drugs whose mechanism of action is TRPC6: Clemizole and Norgestimate.
Which diseases are associated with TRPC6?
The strongest Open Targets associations for TRPC6 are focal segmental glomerulosclerosis, familial idiopathic steroid-resistant nephrotic syndrome, trait in response to prednisolone, nephrotic syndrome and monocyte count.
How long is the TRPC6 protein?
The Homo sapiens TRPC6 protein (UniProt Q9Y210) is 931 amino acids long.
Browse: Targets: T · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9Y210 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9Y210 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.